Globe Artichoke

Artichoke leaf extract inhibits CYP2B6 and CYP2C19 in human liver samples, and shows moderate inhibition of CYP1A2, 2D6, 2E1, and 3A4. This may increase plasma concentrations of CYP-metabolised statins, increasing myopathy risk. Additionally, artichoke compounds (luteolin, cynarin) have intrinsic HMG-CoA reductase inhibitory activity, creating additive lipid-lowering effects. A pharmacokinetic study in rats confirmed artichoke-rosuvastatin interaction.

Monitor for signs of myopathy (muscle pain, weakness, elevated CK) when artichoke leaf extract is combined with statins. High-dose artichoke supplementation alongside simvastatin or lovastatin is of particular concern due to CYP3A4 involvement. Check liver function tests if long-term combined use is planned. Rosuvastatin interaction has been demonstrated pharmacokinetically.

Artichoke leaf extract has demonstrated in vitro inhibition of CYP1A2 and CYP2C9 at high concentrations, both of which are involved in warfarin metabolism (R-warfarin via CYP1A2, S-warfarin via CYP2C9). This may reduce warfarin clearance and increase anticoagulant effect. Additionally, artichoke has choleretic activity that may affect vitamin K absorption.

Monitor INR when patients on warfarin initiate or discontinue artichoke leaf supplementation. Advise patients not to use artichoke supplements in doses beyond culinary amounts without INR monitoring. If INR is found to be elevated above target range after starting artichoke, reduce warfarin dose accordingly.

A published case report (PMID: 28901251) documents severe haematological toxicity, myopathy, and liver toxicity (cholestasis, elevated alkaline phosphatase) in a polymedicated elderly patient who consumed large volumes of artichoke infusion (~1.5 L) while taking colchicine, among other medications. Artichoke may inhibit CYP enzymes involved in colchicine metabolism (CYP3A4, P-gp), leading to colchicine accumulation.

Avoid large amounts of artichoke infusion or high-dose artichoke supplements in patients taking colchicine. Colchicine has a narrow therapeutic index; even modest increases in plasma concentration can cause life-threatening multi-organ toxicity. Warn elderly, polymedicated patients specifically. If artichoke is used medicinally alongside colchicine, close monitoring of full blood count and liver function is essential.

Cynara cardunculus extracts have demonstrated blood glucose-lowering effects via inhibition of alpha-glucosidase and pancreatic lipase, reduction in insulin resistance, and hepatoprotective effects that improve metabolic function. In animal models of streptozotocin-induced diabetes, artichoke extracts significantly reduced blood glucose. Combined with antidiabetic drugs, additive hypoglycaemia risk exists.

Monitor blood glucose closely when artichoke leaf supplements are started in patients on antidiabetic medications. Patients on insulin or sulfonylureas are at greatest hypoglycaemia risk. Educate patients on signs of hypoglycaemia. No specific dose adjustment is required empirically, but increased monitoring frequency is warranted during the first 4-6 weeks of supplementation.

A randomised, double-blind, placebo-controlled clinical trial found that artichoke leaf juice significantly reduced systolic and diastolic blood pressure in patients with mild hypertension after supplementation. The mechanism involves vasodilatory and diuretic effects of chlorogenic acid, cynarin, and luteolin. Combined with antihypertensive drugs, additive blood pressure lowering may cause symptomatic hypotension.

Monitor blood pressure in patients on antihypertensives who begin artichoke supplements. Be alert to symptomatic hypotension (dizziness, lightheadedness). This interaction is considered low risk at dietary doses but moderate with supplemental artichoke extracts. Advise patients with well-controlled hypertension to be cautious.

In vitro studies using human liver microsomes show that artichoke water extracts from wild Egyptian artichoke demonstrate moderate inhibitory activity against CYP2D6. This may increase plasma levels of CYP2D6-metabolised drugs (codeine, tramadol, metoprolol, antipsychotics), potentially causing toxicity or—conversely—reducing conversion of codeine to its active metabolite morphine.

Monitor patients on CYP2D6-sensitive drugs (especially those with narrow therapeutic windows like antipsychotics) who begin artichoke supplementation. For codeine users, artichoke may theoretically reduce analgesic efficacy. For antipsychotics, watch for signs of toxicity. The interaction is theoretical at culinary doses but relevant for medicinal artichoke extract use.